Anxious and bewildered, some drugmakers are reaching out to their lobbyists about how Robert Kennedy’s pending nomination will affect the Food and Drug Administration.
In RFK Jr., drugmakers face an antagonist with regulatory power
Login
0 Comments
Oldest
